---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-014701"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2025-06-11T23:59:59+00:00"
generated_at: "2026-05-19T14:54:39.940846+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health says ARPA-H terminated $10M ENDOinform contract after receiving $3.5M

## Summary
- ARPA-H terminated $10M contract for ENDOinform test on June 9, 2025, citing unmet Milestone 3 specs.
- Aspira had received $2M and $1.5M milestone payments (Nov 2024, Mar 2025) totaling $3.5M.
- Company disputes termination, claims it met all Milestone 3 requirements and was progressing on Milestone 4.
- CEO says R&D team will continue ENDOinform development targeting 2026 completion with shareholder and partner support.
- Contract termination may accelerate development pace due to reduced administrative burden.

## SEC filing metadata
- accession: 0001641172-25-014701
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2025-06-11T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000164117225014701/0001641172-25-014701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000164117225014701/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-014701
- JSON: https://secwatch.observer/filing/0001641172-25-014701.json
- Plain text: https://secwatch.observer/filing/0001641172-25-014701.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.